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The present study investigates the susceptibility of cyto- Abstract Rate constants for the subtilisin-catalyzed proteolytic 
inactivation of cytochrome P450c17 (CYP17), the endoplasmic chrome P450c17 (CYP17) towards degradation by subtilisin 
reticulum membrane-bound fimiting enzyme of gonadal androgen (a non-specific serine endopeptidase; EC 3.4.21.62) as a model 
synthesis, have been determined in the absence and presence of protease. CYP17 (steroid 17c~-monooxygenase/17c~-hydroxy- 
various CYP17 ligands and correlated with fractional enzyme progesterone aldoIase; EC 1.14.99.9/4.1.2.30) is the limiting 
saturation (II). Extrapolation to Y = 1 reveals 15.1-, 4.0- and enzyme of androgen biosynthesis from gestagens in the go- 
7.4-fold enzyme stabilization with progesterone (substrate-type nads; it is a target for complex regulation by lutropin or hu- 
figand), testosterone (product-type ligand) and ketoconazole man choriogonadotropin (hCG) and several other hormones 
(imidazole-type inhibitory ligand), respectively. Structural fea- and paracrine factors [10]. The half-life of CYP17 is shortened 
tures of ligand accommodation can therefore be monitored by the after hCG injection in vivo from 47 h to 6 h, possibly via 
susceptibility of target enzymes to proteolysis. It is further activation of intracellular proteolysis [11], and it has been 
proposed that specific protection of a membrane protein by 
ligand binding during proteolytic digestion may assist in the postulated that androgens accumulating upon gonadotropin 
purification of that protein. Evidence is finally presented that the stimulation promote CYP 17 decay [12]. In view of these ap- 
gonadotropin-induced rapid CYPI7 down-regulation is not parent discrepancies, a complete analysis of ligand concentra- 
promoted by an elevation of steroid hormone levels, tion-dependent modulations of CYP17 proteolysis i therefore 
reported here. It will be proposed that different ligands (at 
Key words." Proteolysis; Protein stabilization; Cytochrome saturating concentrations) decrease the conformational flex- 
P450 (CYP); Gonadotropin; Steroid; Rat testis ibility of this membrane protein and its susceptibility owards 
proteolysis with different efficiencies; this will establish a nov- 
el basis for the understanding of protein structural variations 
1. Introduction after ligand accomodation. 
A multitude of intracellular protein degradation mechan- 2. Materials and methods 
isms are involved in the maintenance of protein compositions 
in specific subcellular compartments, adaptation of protein Microsomal membrane suspensions were prepared by gentle homo- 
concentration to extracellular milieus and accelerated elimina- genization of decapsulated rattestes, followed by repeated differential 
centrifugation exactly as described previously [13]. The final mem- 
tion of oxidatively damaged or misfolded proteins [1-3]. In brane pellets were rehomogenized in 250 mM sucrose, 20 mM Tris 
addition, there are obviously several pathways directing a (pH 7.4) and incubated at a constant final concentration f 0.16 testis 
protein towards degradation, for instance, by covalent post- equivalents/ml corresponding to 1.2 mg protein/ml [14] at a constant 
translational modifications [1,4]. Recently, the potential role temperature of 37°C. Subtilisin (Boehringer, Mannheim, Germany; 83 
of proteolysis in the regulation of cytochrome P450 (CYP) nkat/mg protein lyophilizate with casein as substrate at 37°C) was 
added at various concentrations (ranging from 3 to 50 gg/ml; see 
levels has been investigated. These heme proteins catalyze section 3 and figures). Progesterone, t stosterone (both from Calbio- 
monooxygenations mainly in the membranes of the smooth chem, Bad Soden, Germany) or ketoconazole (a gift from Janssen, 
endoplasmic reticulum leading either to inactivating biotrans- Neuss, Germany) were tested as potentially protective ligands at the 
formations of endo- and xenobiotics or to hydrophobic pre- concentrations specified; ligands were dissolved in methanol (maximal 
solvent concentration 0.3% v/v). After the incubation periods indi- 
cursor transformations towards active metabolites, e.g. steroid cated (range 30-180 min), samples were rapidly cooled and analyzed 
hormones. For the hepatic isoform CYP2E1, ubiquitination immediately. C tochrome P450c17 was measured by active-site itra- 
has been described, especially after enzyme labilization by tion [13] using either progesterone (120 00 1/(mol cm) for the maximal 
inactivating ligands [5,6]. The same enzyme has also been type [ (A387 nm--A420 nm) difference spectrum) or ketoconazole (78000 
l/(mol cm) for the maximal type II (A430 nm--A407 nm) difference spec- 
reported to be degraded by serine proteases located in the trum); back-titrations in the presence ofone or the other ligand were 
endoplasmic reticulum membranes together with their CYP possible since the absorption trough of the progesterone-induced dif- 
substrate [7]. Hormone-induced CYP phosphorylation has ference spectrum corresponds tothe isosbestic point of the ketocona- 
also been suggested to be an initial signal facilitating CYP zole spectrum, whereas the absorption trough of the ketoconazole 
degradation [8,9]. On the other hand, binding of ligands ob- difference spectrum corresponds tothe isosbestic point of the proges- 
terone spectrum. In all cases, control measurements of the dithionite- 
viously stabilizes everal CYP isoforms and protects them reduced+CO minus reduced spectral difference (91 000 1/(mol cm) for 
against phosphorylation and/or proteolytic inactivation A450 nm--A490 ran) yielded identical results for CYP17 concentrations. 
[6,8,9]. In one experiment, the action of subtilisin on microsomal NADPH:- 
cytochrome r ductase (EC 1.6.2.4) was investigated in the presence or
absence of ketoconazole; this activity was measured by the NADPH- 
induced (150 p.M) reduction of 30 gM cytochrome c (20500 l/(mol 
*Corresponding author. Universit~tsfrauenklinik, Biochemische cm) for As~0 nm--A600 rim) [15]. 
Endokrinologie, Moorenstr. 5, D-40225 Dtisseldorf, Germany. For electrophoretic analyses, microsomal membranes were incu- 
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bated for 1 h at 37°C with or without 40 ~tg subtilisirdml and proges- .[ 
terone (30 I.tM) as a ligand. Membrane proteins were centrifuged (45 " K=0.00289/min K=0.001t,3/min 
min, 150000Xg, 2°C) to remove the protease and then subjected to 100. ~ (6lagS/ml} 100-t ~-...~._ (3pgS/ml) 
SDS-polyacrylamide gel electrophoresis [16] (60 min) using precast " \~ ' -o  ~ \ _  - " "~ o ° 
(stacking el, 5%; resolution gel, 8-18°/o acrylamide) gradient gels _--g e0. ~ \  u'~o o 80-~ 
(Pharmacia, Freiburg, Germany). Molecular weight standards were ~ • 
from Boehringer, Mannheim, Germany. Gels were stained with Coo- .°=. 60 60-1 Ik, x l  K=0.01329/min O 
massie blue R250 and scanned with an Ultroscan 2202 laser densit- o . ~ ~ | (25~S/mt) 
ometer (LKB, Bromma, Sweden). ~ t~0. - \  K=0.02td&/min t~0.1 • •NN~ ~S 
An additional experiment was performed to demonstrate hormone- ' t [  (SO pg Sl~l 
induced proteolytic inactivation of CYP17 and its protection by li- .x* 20 Z0.1 .:'h, 
gand binding in tissue directly. For this purpose, decapsulated rat ~. @ ~ ® 
testes were extensively washed in MEM (Minimum Essential Medium ~ 0 . . . . . .  -.~ 0 ' . . . . . . .  
Eagle with Earle's salts; ICN, Meckenheim, Germany), carefully 0 1 2 3 0 1 2 3 
teased apart and then incubated in 10 ml MEM for 3 h at 33°C Incubation time Ihl 
(the physiological scrotal temperature) with or without 10 ktg/ml hu- 
man choriogonadotropin (Primogonyl, Schering, Berlin, Germany); 100 ~ u 100t ~k, x t  " (S0~S/mt. • ~ 2.Slam ketocon.) 
CYP17 ligands (see above) or a mixture of the protease inhibitors ~ 80 mlkw 116"~ • 80-t = ~ I ~ - ~ A  A 
leupeptin (Ac-Leu-Leu-Argininal; 400 lag/ml) plus E64 (N-[N-(L-3- T ' i~kf  ~ t • 
trans-carboxirane-2-carbonyl)-L-leucyl]agmatine; 20 ktg/ml; both '- 
from Boehringer, Mannheim, Germany) were added. After termina- § 60 604 
tion of the incubation, tissue was washed again, and microsomal ~ " • 
membranes were prepared and analyzed for CYP17 concentration "6 ~ 40"1 • 
as described above. .~ K--0.00276/min . • • 
- (SOp.g S/ml + 20-1 Inactivation rate constants K were derived after semi-logarithmic r-- 20 (~ 2.5pt4 progesf.) (~ K=O.OOSOS/min 
transformation f CYP17 concentrations versus incubation times; no K. 
significant deviation from pseudo-first order kinetics was observed. ~ . . . . . . .  0 i . . . . . . .  
0 1 2 3 0 1 2 3 
Dose-effect curves of stabilizing ligand effects were calculated after Incubation time [hi 
logit = log[x/O-x)] transformations of remaining subtilisin activities 
versus log transformation f ligand concentrations [17]. Fig. 1. Time course of cytochrome P450c17 (CYP17) inactivation i
rat testis microsomes (37°C) in the presence of different subtilisin 
(= S) concentrations without (A,B) or with progesterone (C) or ke- 
3. Results toconazole (D) as CYP17 ligands. Curves and inactivation rate con- 
stants K are the result of least-squares linear fitting to pseudo-first 
order kinetics after semi-logarithmic transformation f all individual The microsomal membrane-bound cytochrome P450 en- data points. 
zyme, CYP17, is completely degradable by the non-specific 
protease, subtilisin, although the initial rate of inactivation 
is much slower than with soluble proteins such as casein. 
This difference may partly be due to the use of a crude progesterone, a single additional protein band with Mr 57 400 
CYP17 source; membrane preparations contain roughly appears (Fig. 2D), which corresponds exactly to the reported 
0.8% CYP17 related to total membrane protein. Notwith- molecular mass of CYP17 (Mr 57 100 [10]). A tentative corre- 
standing, the time courses of CYP17 decay reveal the exist- lation of protein band absorptions after densitometric scan- 
ence of a pseudo-first order process. Inactivation rate con- ning (based on the mean of the seven standard proteins: Fig. 
stants are proportional to the protease concentration over a 2A) yields an amount of approx. 40-50 ng protein in the 57.4 
3-50 gg subtilisin lyophilizate/ml concentration range (Fig. kDa band. This value would correspond to about 1.0-1.2 
1A,B). In the presence of the physiological (in the rat testis) nmol CYP17/testis equivalent; this amount is only slightly 
CYP17 substrate, progesterone (Fig. 1C), as well as in the (20%) higher than that found spectroscopically in untreated 
presence of the broad-spectrum CYP inhibitor, ketoconazole rat testis microsomes. Unspecific proteolytic attack of micro- 
(Fig. 1D), the pseudo-first order inactivation rate constants somal membranes and specific ligand protection of CYP17 
are significantly reduced when compared to the unprotected, thus result in a significant relative enrichment of this protein. 
ligand-free CYP17. Time courses further indicate that there is Since the mean pseudo-first order inactivation rate con- 
no obvious metabolism or inactivation of the ligands during stants determined in the presence of a given ligand concentra- 
incubation, tion are resultants from the K values of the free and of the 
The target specificity of this effect was demonstrated by ligand-occupied CYP17 molecules, the fractional saturation Y
subtilisin action on NADPH:cytochrome reductase in testis has a profound effect. With 2.5 gM of either progesterone 
microsomes. This enzyme, which has a greater portion outside (spectral dissociation constant Ks = 0.16 gM) or ketoconazole 
the membrane than CYP17, was more rapidly inactivated (by (Ks = 0.28 ~tM), Y amounts to 0.94 and 0.90, respectively. 
a factor of 1.8) than CYP17 with 10 gg/ml subtilisin, but there After correction for this difference, the inactivation rate con- 
is no protective ffect of either ligand (up to 5 gM; data not stants are 0.00137 min -1 for the CYP17-progesterone and 
shown). 0.00382 min -1 for the CYP17-ketoconazole complexes 
The selectivity and efficiency of CYP17-1igand complex re- (Y = 1), respectively, in contrast to 0.02444 min -1 for the 
sistance against proteolytic breakdown are further realized on free (Y = 0) CYP17. In conclusion, ligand binding to 
the basis of electrophoretic comparisons (Fig. 2). Subtilisin CYP17 protects this protein effectively, but not completely 
(40 ~tg, 1 h) causes nearly complete degradation of microso- against proteolytic attack by subtilisin, and this process ap- 
mal proteins into smaller peptides which probably remain in- pears to vary with ligand structure. 
accessible to proteolytic attack from the water phase (Fig. 2, This momentous conclusion is corroborated by analyses of 
lanes B,C; sample concentration (testis equivalents) is 4-fold the concentration dependence of the protective ffect of three 
higher in C,D than in sample B). In the presence of 30 ~tM different CYP17 ligands, viz. progesterone, ketoconazole and 
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testosterone (the final product of testicular androgen bio- 
synthesis and short-loop feedback inhibitor of C Y P 1 7 ; p r e s e n c e  ~l°°It,~. ~ ~ ~ # •  [I • 
Ks = 12 ~tM), in the of two different subtilisin and .~  
one constant substrate (microsomal CYP17) concentrations 80 
(Fig. 3). The residual subtilisin activities decrease with increas- ~ 60t 
ing ligand concentrations in the typical fashion reflecting li- ~ • 
gand binding to enzymes or receptors. Ligands appear to be ~°  1 -, I'B"',~ ~",A _KN,: 
® ; ; , '< 
t , 00gs,o, o 
o 
0.08 0.31 1.25 5.0 20 80 320 
[Ligond l [IJH] 
o 
.~ 100" ^ 01 : progesterone 
• : ;~  & = ketotonozole 
• - \  
20. 
S/ml 
0.b8 ' 0.'~ ' ~.~s ' 5.b ' 2b ' a'0 ' ~0  
[Ligllnd ] [blHl 
Fig. 3. Dose dependence of progesterone- (squares), ketocona- 
zole- (triangles) or testosterone- (diamonds) induced protection of 
cytochrome P450c17 (CYP17) in rat testicular microsomes against 
proteolytic inactivation (37°C, 3 h) by two different (A,B) subtilisin 
(= S) concentrations. All single measurements are normalized to the 
corresponding control activity of subtilisin towards CYP17 without 
ligand. The curves are the resultants of least-squares linear fitting 
after logit-log transformation. 
more effective with lower protease concentrations; the IC~0 
(50% inhibitory concentration) values are 0.27 vs. 0.79 ~tM 
progesterone, 0.62 vs. 3.6 ~M ketoconazole and 31 vs. 110 
IxM testosterone, respectively, with either 10 or 40 ~tg subtili- 
sin/ml assay. This difference is, however, simply a consequence 
of varying inactivation rate constants for Y = 1 with the dif- 
ferent protease activities; it disappears if the data are trans- 
formed by plotting the actual inactivation rate constants K
against he actual fractional saturations Y, followed by calcu- 
lation of the ratios K(Y = 1) vs. K(Y = 0) for each pair of 
rates (Fig. 4). These ratios are independent of the protease 
concentration applied but are significantly lower for proges- 
terone than for ketoconazole (P < 0.005) and also lower for 
ketoconazole than for testosterone (P < 0.02) (Fig. 4). 
A final experiment indicates that proteolytic degradation of 
CYP17 may be involved in the regulation of rat testicular 
function. If decapsulated testes are incubated for 3 h with 
10 ~g/ml human choriogonadotropin, the content of CYP17 
in microsomes prepared from the organs drops from 553 + 37 
(3 h control value without hCG; ~+S.E.M.; n= 7) to 
A ~ C D 339+31 pmol/testis equivalent (P < 0.001). Addition of a 
, ~ mixture of leupeptin and E64 to the organ incubation assays 
with hCG restores CYP17 to 582 + 34 pmol/testis, indicating 
Fig. 2. Protein distribution pattern in SDS-polyacrylamide g l elec- involvement of proteolytic activities in this hormone action. 
trophoresis of testicular microsomal proteins before (0.001 testis 
equivalents/lane; B) or after subtilisin treatment (40 ~tg/ml, 1 h, Similarly, addition of 15 txM ketoconazole also prevents 
37°C, 0.004 testis equivalents/lane) without (C) or with 30 IxM pro- CYP17 from putatively hCG-induced proteolysis (584 + 21 
gesterone (D). Standards (30~420 ng protein/band; A) are, from pmol/testis); in the presence of 50 I.tM testosterone, 540 
top to bottom: 13-galactosidase (Mr 116400), fructose-6-phosphate pmol CYP17/testis (n = 2) are found. This is a first indication 
kinase (85 200), glutamate dehydrogenase (55 600), aldolase (39 200), 
triosephosphate isomerase (26 600), trypsin inhibitor (20100), and ly- that ligand protection of CYP17 against proteolytic inactiva- 
sozyme (14300). Note the additional band appearing in lane D (vs. tion may be a relevant process not only in artificial systems in 
C) at Mr 57 400. vitro but in situ as well. 
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_ r-------- testosterone, which lacks the D-ring side-chain with the im- 
| ~&2~ 401ag(ll'A'#--$/ml) portant oxo group at C-20, is a much weaker ligand than 
~o2 •n ~ n~IL_  0z o progesterone based on the magnitude of maximal low-spin 
v n--~6 to high-spin transitions upon binding. If it is accepted that 
- ] ~  ~"~m (~) flexibility versus rigidity of certain exogenously accessible do- 
i t101 a0 ~ "~ '~ mains on a protein surface ('degrons') determines its suscept- 
n ibility towards proteolytic attack [2,18], and if it is further 
accepted that ligands increase the rigidity of such domains 
0 . . . .  [18], it can be concluded that progesterone 'fits' the CYP17 
0 0.5 1 0 05 i ligand-binding cavity better than testosterone with respect o Y (£YP17. progesterone) 
reinforcement of CYP17 structure. Ketoconazole is an effec- 
I t  ~ ~ (o,zx,O = rive inhibitory ligand of CYP17 [22], but has originally been 
~°-2i _ I 10pgs/mtl designed as a lanosterol mimic, blocking the lanosterol 14ct- 
~0 ~ methyl demethylase r action sequence. It is therefore compre- 0 _ 1~(~) A  4 ~ ~  hensible that this ligand is also less effective than progesterone 
i ~ in protecting CYP17 by reduction of its conformational flex- 
0.01 ~00z t~ ibility. It is anticipated that the chosen approach may assist in 
improved elucidation of cytochrome P450 structures, espe- 
0 0 cially if refined by the use of more specific proteases [23] 
o 03 1 6 o15 1 and further ligands. 
V (CVP17.ketoconozole) As for methodological implications, it is tentatively pro- 
~ ] ~ ~ ~ 0 ~ " ~  ~ I posed that the specific retention ofamembrane-associated $ 
~2 enzyme by binding of a protective ligand under conditions 
0.00 
0 L_UlIU_A J where the majority of other proteins is proteolytically digested 
#~,,,.,~ . ~ n=26 [ t ~ . ~  may be useful as an initial step in preparative procedures to 
I ~ J 00034 obtain the protein in question. One remarkable advantage is
0~ # I~ ~1I,..1I~ I ~ the maintenance of the physiological membrane nvironment 
@ "~/~1 0j C) ~ which has repeatedly been demonstrated to affect the function 
of such membrane-bound enzymes [24]. 
6 0'.5 i 6 0~s i As for the functional implications of this study, it must be 
Y (£YP17,testosterone) concluded that proteolysis is involved in the gonadotropin- 
Fig. 4. Pseudo-first order inactivation rate constants (K) vs. frac- induced down-regulation of rat testicular CYP17, and that 
tional enzyme saturation (Y) plot of cytochrome P450c17 (CYP17) this process can be antagonized by ligand binding-induced 
inactivation by two different (A,C,E vs. B,D,F) subtilisin (= S) con- enzyme protection. Although it is improbable that steroid 
centrations in the presence of progesterone (A,B), ketoconazole 
(C,D) or testosterone (E,F). Data are identical to those presented in (progesterone as the substrate and testosterone as the final 
Fig. 3; Y values were taken from spectrophotometric titrations of li- product) concentrations become high enough to be completely 
gand binding. The lines connect he mean values of K(Y = 0) and protective after hCG stimulation, it appears that these ligands 
of K(Y = 1) obtained separately for the data sets in each of the six do not labilize the CYP17 enzyme as occasionally suggested. 
diagrams. For calculations of the stabilization ratios K(Y= 1)/ 
K(Y = 0), data were combined from assays with low and high subti- A 'pseudo-substrate type' of steroid binding has been hy- 
lisin concentrations; probabilities for significant differences are given pothesized, leading to an abortive activation of oxygen and 
in the text. oxidative damage of CYP17 [12,25]. The present results sug- 
gest that this mechanism does not account for gonadotropin- 
induced degradation of CYP17 in the rat testis. 
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